Ophthalmologist Jason Ehrlich launched Ollin Biosciences with $100 million in funding to develop novel antibody therapeutics aimed at eye diseases. The company's lead bispecific antibody, OLN324, targets VEGF and Ang2 to improve on Roche’s Vabysmo, currently the leading treatment for age-related macular degeneration and diabetic macular edema. Ollin’s portfolio also includes OLN102, targeting thyroid eye disease. These programs leverage Chinese biotech partnerships and aim to offer superior efficacy and administration convenience.